Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Jan;11(1):80-91.

Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea

Marwan N Sabbagh  1 , Holly A Shill
Affiliations
Review

Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea

Marwan N Sabbagh et al. Curr Opin Investig Drugs. 2010 Jan.

Abstract

Latrepirdine (Dimebon) is a small-molecule compound under development by Medivation Inc and Pfizer Inc for the treatment of Alzheimer's disease and Huntington's chorea. Originally developed and marketed as an antihistamine in Russia, latrepirdine has since demonstrated potential for the treatment of neurodegenerative diseases. Early research suggested that the mechanism of action was centered on AChE inhibition and NMDA antagonism. More recent research questions these early findings, and other mechanisms of action have been proposed and investigated. In phase II clinical trials, latrepirdine demonstrated clinically relevant improvements in patients with Alzheimer's disease and Huntington's chorea. At the time of publication, phase III clinical trials had been initiated. Given the robustness of the phase II clinical data, latrepirdine has a high likelihood of success in phase III trials and in subsequently being granted regulatory approval.

PubMed Disclaimer

References

    1. Riluzole therapy in Huntington’s disease (HD) Rosas HD, Koroshetz WJ, Jenkins BG, Chen YI, Hayden DL, Beal MF, Cudkowicz ME. MOV DISORD. 1999;14(2):326–330. - PubMed
    1. Increased oxidative damage to DNA in a transgenic mouse model of Huntington’s disease. Bogdanov MB, Andreassen OA, Dedeoglu A, Ferrante RJ, Beal MF. J NEUROCHEM. 2001;79(6):1246–1249. - PubMed
    1. Alzheimer disease in the US population: Prevalence estimates using the 2000 census. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. ARCH NEUROL. 2003;60(8):1119–1122. - PubMed
    1. Pres Release. Medivation Inc; 2005. Sep 09, Medivation announces first patient dosed in phase II trial with 3 for treating Alzheimer’s disease.
    1. FORM 10-K. Medivation Inc; 2005. May 02, Orion Acquisition Corp II – Form 10-K.

Publication types

MeSH terms

LinkOut - more resources